Fundraising Fox

Triumvira Immunologics

Austin, US · Founded 2015 · Ontario, Canada corporation · 21 employees on LinkedIn · 3 known investors

Find your way into Triumvira Immunologics

227 people in our graph share verified history with the Triumvira Immunologics team — schools, employers, funds. One of them is your warm intro.

Chris Robinsonunlockedknows PAUL LAMMERS, MD, MSc · together at EMD Serono, Inc. (overlapped)
×4knows the team · via Radboud University
×2knows the team · via University of Illinois Urbana-Champaign
×3knows the team · via Columbia Business School
knows the team · via Price Waterhouse
knows the team · via EMD Serono, Inc.

Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.

BiotechHealthtechMedical Devices

Founders & leadership

TM
TERESA MCROBERTSinChief Financial Officer2021–2023Teresa McRoberts joined Triumvira Immunologics as CFO in early 2021, bringing two decades of healthcare portfolio management and investment banking experience. Her background includes roles in healthcare-focused investing, M&A, capital raising, and financial strategy for biotechnology companies.
PLPAUL LAMMERS, MD, MSc
PAUL LAMMERS, MD, MScinChief Executive Officer2018–2024Paul Lammers is a physician and biopharmaceutical executive who has held leadership positions at public and private companies, with therapeutic experience across women's health, men's health, neurodegenerative diseases, metabolic disorders, orphan diseases, and oncology.
JIJON IRVIN
JON IRVINinConsultant2023–2024He brings extensive experience in financial management across biotechnology, medical devices, software, and high-technology companies, ranging from early-stage ventures to mature organizations, and has been involved in over $650 million in public and private financings.

Board

DJ
DANIEL JANSEBoard director
JE
JURGEN ECKHARDTBoard director
EW
ELIZABETH WILLIAMSBoard director
WMWIDYA MULYASASMITA
WIDYA MULYASASMITAin𝕏Board of Directors2022–2023Principal at B Capital Group
BM
BRIAN M. BLOOMBoard director
LC
LEE COOPERBoard director
CC
CYNTHIA COLLINS, MBABoard director
SS
SCOTT SMITHBoard director

Investors · 3

B Capital GroupManhattan Beach · $10M – $50M
B4 Capital$10M – $50M
Checkmate Capital Group LLCPasadena

Reported raises · per SEC filings

Form D private placements

$59.7M disclosed across 1 round · 2021

▶$59.7MraisedSep 2022 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CYNTHIA COLLINS, MBADirector
  • SCOTT SMITHDirector
  • DANIEL JANSEDirector
  • JURGEN ECKHARDTDirector
  • TERESA MCROBERTSExecutive Officer
  • PAUL LAMMERS, MD, MScExecutive Officer, Director
  • ELIZABETH WILLIAMSDirector
  • JON IRVINExecutive Officer
  • WIDYA MULYASASMITADirector
  • BRIAN M. BLOOMDirector
  • LEE COOPERDirector
Offering amount
$59.7M
Amount sold
$59.7M
First sale
Apr 2021
Incorporated
Corporation, Ontario, Canada
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Triumvira Immunologics do?
Triumvira is a clinical-stage immuno-oncology company developing autologous and allogeneic T cell therapeutics for cancer treatment. The company applies T cell biology and targeted immunotherapy approaches to address oncology.
Who are Triumvira Immunologics's investors?
Triumvira Immunologics's investors include B Capital Group, B4 Capital, Checkmate Capital Group LLC.
How much funding has Triumvira Immunologics raised?
Triumvira Immunologics has disclosed $59.7M raised across 1 round.
Where is Triumvira Immunologics headquartered?
Triumvira Immunologics is headquartered in Austin, US.